MO-PIERIANDX
4.2.2021 11:02:10 CET | Business Wire | Press release
PierianDx, the global leader in clinical genomics knowledge, today announced a partnership with the Belgian Society of Medical Oncology (BSMO) to study the impact of comprehensive genomic profiling (CGP) on clinical outcomes of late-stage cancer patients. As part of the study, nine sites across Belgium will use the PierianDx interpretation and reporting solution, Clinical Genomics Workspace™ (CGW), to help determine the best therapeutic options for treatment.
Current approaches to precision medicine testing often mean that tests are outsourced to large international organizations or that they are run by independent regional labs, neither of which result in standardized clinical care systems or improved collective knowledge. In response to these challenges, the BSMO has established the BALLETT (Belgian Approach for Local Laboratory Extensive Tumor Testing) study to evaluate the impact of CGP.
CGP uses next-generation sequencing (NGS) to analyze hundreds of genes and biomarkers in tissue samples from biopsies or blood and detect those that are clinically relevant in driving cancer growth. Illumina will provide its CGP panel for tissue samples, TruSight™ Oncology 500 (TSO500), and NovaSeq™ 6000 and NextSeq™ sequencing platforms for the study. Clinical interpretation of the sequencing data will be carried out using the PierianDx Clinical Genomics Workspace™ (CGW) solution.
CGW provides a streamlined, standardized analysis platform in which EU drug approvals and guidelines are matched to complex genetic variants detected in patient tumor DNA and RNA, all within a GDPR-compliant environment. Using the platform, the nine participating Belgian laboratories can collaboratively review variant pathogenicity and clinical impact for their local samples while also benefiting from the knowledge of other clinical laboratory CGW users from around the world. At the same time, the nine Belgian laboratories will provide this standardized testing and analysis close to the patient’s home, where they receive cancer care, accelerating treatment initiation. As this study will also monitor the patient outcomes during and following treatment, a true indication of those longer-term clinical benefits will be derived.
Dr. Brigitte Maes of the Jessa Hospital in Belgium, Coordinator of BALLETT study said, “As part of Belgium’s broad approach to advancing precision medicine the study will generate valuable insights into the value of CGP versus currently reimbursed sequencing approaches. For example, in addition to genetic mutations that drive cancer formation, CGP will also identify cancers driven by the TMB biomarker which can guide patients towards immunotherapy treatments. This means that the study will give access to additional treatments which may not have been considered through more traditional diagnostic testing.”
Dr. Rakesh Nagarajan, Founder of PierianDx states, “We are ecstatic to be part of this groundbreaking study. The CGW platform is in use by over 25 countries to share knowledge and facilitate better treatments and patient outcomes, and now the clinicians involved in this study will benefit from this collective knowledge while incorporating European-specific data sources, which are curated and maintained by PierianDx.” He adds, “Not only will this study measure the impacts of CGP but it will provide a justification, framework, and a blueprint for other clinical laboratories around the world that wish to implement similar initiatives.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. For more information visit www.pieriandx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hightouch Partners with Independent Media to Activate Reader and Commercial Data27.10.2026 17:01:00 CET | Press release
The partnership will help Independent Media deliver more relevant reader engagement, build premium advertising audiences, and support affiliate and e-commerce growth. Hightouch, the leading agentic marketing platform, today announced a partnership with Independent Media, publisher of The Independent. Independent Media will use Hightouch to connect its customer data to marketing tools. With Hightouch, the company will send readers more relevant membership and subscription offers, build stronger audiences for its advertising partners, and grow its affiliate and e-commerce business. “Deepening customer relationships and delivering real value to our commercial partners requires moving seamlessly from insight to action,” said Krishan Gandhi, Director of Data Intelligence and Monetisation at Independent Media. “Partnering with Hightouch allows us to utilise our warehouse data directly into our engagement tools, powering real-time, omnichannel journey orchestration, while enabling us to build
IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era27.10.2026 16:00:00 CET | Press release
New research reveals how smaller, more intentional eating occasions are creating new opportunities for nutrition, flavor and renewed enjoyment. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, “GLP-1 Consumer Moments of Opportunity.” The report uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026614988/en/ New report from IFF uncovers ten emerging consumer moments that reflect the changing needs of consumers using GLP-1 medications. “What GLP-1 users need from food and beverage products depends on the moment, and those needs can change many times throughout the day,” said Yuvraj Arora, president of IFF Taste. “The most successful innovations will be designed around the occasions that matter most to consumers, delivering the right balance of nutrition
Phison Receives Micron Global Supplier Awards27.10.2026 15:00:00 CET | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, is honored to announce that it was presented with Outstanding Supplier Performance Awards in the Semiconductor category and the Best in Quality – Assembly and Test categoryat the Micron Supplier Day 2026. The event, held in Boise, Idaho, United States was attended by top-level management of Micron and its suppliers, including Phison. The awards highlight our commitment to excellence in quality, innovation and collaboration with Micron, a global leader in semiconductor memory and storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027158504/en/ Phison wins Outstanding Supplier Performance Award in Semiconductor category and the Best in Quality – Assembly and Test category at the Micron Supplier Day 2026 “Receiving our third Micron Supplier Award in a row is a tremendous honor and a testament to the strength of our partnership
MUFG Investor Services Appoints McAllister Kirschner Chief Executive Officer27.10.2026 14:15:00 CET | Press release
MUFG Investor Services today announced the appointment of McAllister (Mac) Kirschner as Chief Executive Officer, effective immediately. John Sergides has stepped down as Chief Executive Officer of MUFG Investor Services for health-related reasons. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027545977/en/ McAllister (Mac) Kirschner Appointed Chief Executive Officer of MUFG Investor Services Kirschner has served as Chief Operating Officer of MUFG Investor Services since 2018, overseeing business and banking operations across public and private markets. He joined MUFG Investor Services in 2016 and previously served as Global Head of Relationship Management, bringing extensive knowledge of the business, its clients, and operations. Before joining MUFG Investor Services, Kirschner was a Managing Director in BlackRock’s Global Fund Services business, where he led teams responsible for shareholder servicing, fund administrati
FEINDEF 27 Has Already Booked 94% of Its Exhibition Space Seven Months Ahead of the Event27.10.2026 14:03:00 CET | Press release
The International Defence and Security Exhibition of Spain (FEINDEF 27) has booked 94% of its exhibition space for 18 to 20 May 2027 at IFEMA Madrid, reflecting strong demand and interest among companies and institutions across the sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027170443/en/ Ángel Olivares, President of the Feindef Foundation Fundación Feindef announced the figure on Monday at the official presentation of the exhibition's fifth edition, held at Madrid's Rafael del Pino Auditorium. The fair is expected to cover more than 89,000 square metres, 46% more than in 2025. More than 746 exhibitors have been confirmed, up 19% on the previous edition. Of these, 37% are first-time participants and over 250 are international exhibitors, accounting for 33% of the total. The event will feature 14 international pavilions, strengthening its international reach as the defence and security industry gains prominence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom